Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
2.100
-0.035 (-1.64%)
At close: Sep 8, 2025, 4:00 PM
2.100
0.00 (0.00%)
After-hours: Sep 8, 2025, 4:16 PM EDT
Ensysce Biosciences Employees
As of December 31, 2024, Ensysce Biosciences had 8 total employees, including 7 full-time and 1 part-time employees. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
$926,715
Profits / Employee
-$822,697
Market Cap
6.23M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8 | 1 | 14.29% |
| Dec 31, 2023 | 7 | 0 | - |
| Dec 31, 2022 | 7 | 1 | 16.67% |
| Dec 31, 2021 | 6 | 3 | 100.00% |
| Dec 31, 2020 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ENSC News
- 4 days ago - Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium - Accesswire
- 20 days ago - Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025 - Accesswire
- 24 days ago - Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) - GlobeNewsWire
- 26 days ago - Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates - Accesswire
- 5 weeks ago - Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback - Accesswire
- 7 weeks ago - Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse - Accesswire
- 2 months ago - Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2 - Accesswire
- 3 months ago - Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025 - Accesswire